Sanofi’s Phase 3 CNS therapeutics have generated four Investigational New Drug (IND) applications and over 104 clinical studies in more than 15,000 subjects
Terran Biosciences signs licensing deal with Sanofi. (Credit: Christina Victoria Craft on Unsplash)
Terran Biosciences, a US-based biotech company, has reached an agreement with Sanofi to obtain exclusive global rights to develop and commercialise the latter’s two late-stage CNS portfolio assets.
The US-based biotech company is focused on developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.
Sanofi’s pipeline products are said to have generated four Investigational New Drug (IND) applications and over 104 clinical studies in more than 15,000 subjects across various CNS indications.
Terran intends to rapidly advance the development of CNS portfolio assets it has licensed from Sanofi, for neurological and psychiatric indications.
The transaction, which indicates a step-up in the development of the assets, includes an upfront payment along with milestone payments and royalties.
Terran founder and CEO Sam Clark said: “We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry.”
Earlier this month, Terran signed an agreement with Blumentech to acquire the latter’s complete portfolio of patents related to psychedelic compounds and associated data.
Terran said that the patents it had acquired from Blumentech would further complement its rapidly growing IP portfolio of more than 150 patent applications in the psychedelic space.
The portfolio includes patents on the company’s orally-active DMT compound, which is a result of its medicinal chemistry drug discovery programme.
Furthermore, the transaction includes data and patent rights licensed from several academic institutions in Spain.
The institutions include Fundació Institut de Recerca de l’Hospital de La Santa Creu i Sant Pau, Universidad Autónoma de Madrid, State Agency Consejo Superior de Investigaciones Cientificas, and Consorcio Centro de Investigación Biomédica en Red.